Rodman & Renshaw analyst Brandon Folkes initiated coverage of Milestone Pharmaceuticals with a Buy rating and $9 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals’ Promising Drug Advancements
- Milestone Pharmaceuticals Eyes 2025 for CARDAMYST Launch
- Milestone Pharmaceuticals reports Q2 EPS (14c), consensus (19c)
- Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
- Milestone Pharmaceuticals Bolsters Board with New Directors